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Background: Haemodilution and hypothermia induce coagulopathy separately, but their combined effect on
coagulation has not been widely studied. Fibrinogen concentrate can correct dilutional coagulopathy and has an
additional effect when combined with factor XIII concentrate. However, their effect on dilutional coagulopathy
concomitant with hypothermia has not been studied previously. Free oscillation rheometry – FOR (ReoroxW) – is a
novel viscoelastic haemostatic assay that has not been studied in this context before.
Methods: Blood from 10 healthy volunteers was diluted by 33% with hydroxyethyl starch or Ringer’s acetate
solutions. Effects of fibrinogen added in vitro with and without factor XIII were studied at 33°C and 37°C.
Coagulation velocity (coagulation time) and clot strength (elasticity) were assessed with FOR. Coagulation was
initiated in vitro with thromboplastin alone, or thromboplastin plus a platelet inhibitor.
Results: Hydroxyethyl starch increased the coagulation time and decreased clot strength significantly more than
Ringer’s acetate solution, both in the presence and absence of a platelet inhibitor. There was a significant
interaction between haemodilution with hydroxyethyl starch and hypothermia, resulting in increased coagulation
time. After addition of fibrinogen, coagulation time shortened and elasticity increased, with the exception of
fibrinogen-dependent clot strength (i.e., elasticity in the presence of a platelet inhibitor) after hydroxyethyl starch
haemodilution. Factor XIII had an additional effect with fibrinogen on fibrinogen-dependent clot strength in blood
diluted with Ringer’s acetate solution. Hypothermia did not influence any of the coagulation factor effects.
Conclusions: Both haemodilution and mild hypothermia impaired coagulation. Coagulopathy was more
pronounced after haemodilution with hydroxyethyl starch than with Ringer’s acetate. Addition of fibrinogen with
factor XIII was unable to reverse hydroxyethyl starch induced clot instability, but improved coagulation in blood
diluted with Ringer’s acetate solution. Fibrinogen improved coagulation irrespective of hypothermia.
Keywords: Free oscillation rheometry, Thrombelastography, Coagulation factor concentrate, Fibrinogen, Factor XIII,
Haemodilution, Hypothermia, Coagulopathy, Hydroxyethyl starch, Ringer’s acetate solutionIntroduction
Exsanguination is the second most common cause of
death in major trauma after central nervous system
(CNS) injury [1,2]. To maintain an adequate circulatory
blood volume and oxygen carrying capacity, traumatic
and surgical haemorrhages are generally initially
compensated for by administrating a combination of* Correspondence: dag.winstedt@med.lu.se
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reproduction in any medium, provided the orcrystalloids, colloid solutions and packed red blood cells
(PRBC). However, this results in haemodilution,
hypothermia and acidosis, thus promoting the coagu-
lopathy often seen in major haemorrhage [3,4]. In
addition, synthetic colloid solutions such as hydro-
xyethyl starch affect coagulation more than crystalloid
solutions do [5,6].
Fibrinogen is the first coagulation factor to reach crit-
ical levels in major haemorrhage [7] and fibrinogen con-
centrate should be given in active bleeding when plasma
levels reach 1.5 to 2.0 g/l [8]. This increases clot stabilityal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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may improve survival [14,15]. The benefit of fibrinogen
concentrate may be augmented by factor XIII (FXIII),
since FXIII is responsible for cross-linking fibrin mono-
mers [16].
Viscoelastic haemostatic assays (VHA), such as thrombe-
lastography (TEG) and rotational thrombelastometry
(ROTEM), may better guide blood component therapy in
major bleeding compared to traditional coagulation tests
[4,17]. According to analysis with VHAs, coagulation is
impaired by both hypothermia [18,19] and haemodilution.
In this study, we analysed coagulation with free oscillation
rheometry (FOR), a novel viscoelastic haemostatic assay.
The aim of our study was to investigate hypothermia-
and haemodilution-induced coagulopathy measured with
free oscillation rheometry, and to what extent this
coagulopathy could be reversed with fibrinogen concen-
trate, combined with or without FXIII. Our hypotheses
were that hypothermia and haemodilution would each
impair coagulation measured with FOR and that the
combination of hypothermia and haemodilution would
interact, that is would impair coagulation synergistically.
We also hypothesised that fibrinogen could reduce this
coagulopathy, with an additional effect of FXIII.Materials and methods
Study subjects and sampling
Ten healthy individuals without any known coagulation
disorder (one woman and nine men, average age 43 -
years, with a mean haemoglobin level of 150 g/l) gave
their written informed consent to donate 50 ml of blood.
None of the subjects had taken any medication, includ-
ing naturopathic preparations, during the seven days be-
fore blood collection. The Ethical Board, Lund, Sweden,
approved the study (Registration Number: DNR 484).
Venipuncture was performed with a 21G needle and
blood was collected into plastic VacutainersW, mixing
one part of citrate with nine parts of blood (BD,
Plymouth, UK (citrate 0.129 mmol/l)). Blood was col-
lected on two occasions on the same day per individual.
The tubes were incubated for a minimum of 30 minutes
and a maximum of four hours at a temperature of 33° or
37°C to ensure temperature equilibration.Haemodilution
Blood was diluted 33% with either Ringer’s acetate solu-
tion (RA) (Fresenius Kabi, Bad Homburg, Germany) or
with 6% hydroxyethyl starch in saline (HES) (Mw
130 kDa, substitution 0.42, B. Braun, Melsungen,
Germany). The solutions had a temperature of 33° or 37°C
and the haemodiluted samples were kept at a temperature
of 33° or 37°C until coagulation was analysed.Coagulation factor concentrates
Fibrinogen concentrate (HaemocomplettanW, now renamed
RiastapW, CSL Behring, Marburg, Germany) was dissolved
in distilled water (Fresenius Kabi) to a concentration of
20 g/l. FXIII concentrate (FibrogamminW, CSL Behring)
was dissolved in the solvent supplied by the manufacturer
to a concentration of 62.5 U/ml. 120 μl of fibrinogen alone
or 120 μl of fibrinogen supplemented with 15 μl of FXIII
were added to a total sample volume of 3000 μl. These
amounts correspond to therapeutic doses used in clinical
practice: 4 g fibrinogen and 1550 U of FXIII to a 70-kg
man, i.e., 55 mg fibrinogen and 22 U of FXIII per kg of
body weight [20].
Coagulation analysis
Clot formation and clot strength was studied with free
oscillation rheometry (FOR), assessed with the ReoRox
G2W rheometer (Medirox AB, Nyköping, Sweden). FOR,
like thrombelastography, utilizes an oscillating move-
ment to monitor coagulation. The sample is added to a
reaction chamber, which consists of a gold-coated sam-
ple cup with a gold-coated cylinder (bob) suspended in
the blood sample [21]. FOR uses a torsion wire system
to set the sample into oscillation (Figure 1). A magnet
pulls back the measuring head connected to the torsion
wire. On release, the torsion wire will set the cup into
free oscillation and its movement is recorded by an op-
tical detector. The changes of damping and frequency of
the oscillation correlates to viscosity and elasticity re-
spectively, which are recorded as a viscosity curve and
an elasticity curve (Figure 1).
The coagulation time (COT) is obtained from the vis-
cosity curve. Coagulation time 1 (COT1) is the time to the
start of clot formation when the initial strands of fibrin are
formed [22]. Coagulation time 2 (COT2) is the time to
complete clot formation after which elasticity starts build-
ing up and is equivalent to CT time for ROTEM. The clot
strength in terms of maximum elasticity (G'max) is deter-
mined from the elasticity curve [23] and G'max is equiva-
lent to MCF for ROTEM.
All analyses were performed according to the manufac-
turer’s instructions. Sample cups were placed into the
heating blocks of the apparatus which were set to either
33° or 37°C. Temperatures were allowed to equilibrate and
1000 μl of blood sample was added to each sample cup.
After re-calcification with 25 μl of 0.5 M CaCl2 (Medirox
AB), coagulation was initiated with thromboplastin alone
(FibScreen1, Medirox AB) or thromboplastin in the pres-
ence of abciximab (FibScreen2). Abciximab is a glycopro-
tein IIb/IIIa-receptor antibody and thus, inhibits platelet
interaction with fibrinogen. Accordingly, FibScreen2 (Fib2)
provided information about the functional fibrinogen con-
centration and fibrin stability of the clot. FOR tracings
were analyzed for COT1, COT2 and G'max. G'max was
Figure 1 Free oscillation rheometry. The ReoRox G2 rheometer (upper left corner) and a schematic picture of its free oscillation sample cup
(upper right corner). The magnet turns the sample cup around the torsion wire. Upon release, an oscillatory movement starts which is recorded
by an optical detector. The change in damping generates a viscosity curve (dashed line) and the change in frequency generates an elasticity
curve (full line) as shown in A. The damping (viscosity) of the oscillation increases as the sample coagulates until all is coagulated at which point
the viscosity returns to baseline since the damping of the oscillation will not be affected anymore. This is followed by an increase in oscillation
frequency (elasticity) when the platelets retract the clot. The height of the elasticity curve represents the strength of the clot. Variables detected
are indicated with arrows (COT1- time to beginning of clot formation, COT2 – time to complete clot formation and Max elasticity (G'max) –
maximum clot strength). B shows the differences in elasticity between FibScreen1 (full black line) and FibScreen2 (full grey line). The viscosity
(COT1 and COT2) for FibScreen1 (dashed grey line) and FibScreen2 (dashed dotted line) is similar in a normal sample. Normal ranges are
presented in the figure.
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(Fib1) and for whole blood with inhibited platelets using
Fib2 as activator. The difference in G'max between Fib1
and Fib2 was calculated as a measure of platelet-dependent
clot strength. The normal ranges for the FOR parameters
according to the manufacturer are presented in Figure 1.
The coefficients of variation (CV) for the FOR parameters
were 3% for COT1, 9% for COT2, 11% for Fib1 G'max and
15% for Fib2 G'max. The lowest detection level of G'max is
set to 10 Pa in the software, which is well above the normal
range for Fib2 G'max, and thus FOR should be able to de-
tect low levels of functional fibrinogen concentrations.
Statistical analysis
Kolmogorov-Smirnov tests were significant for several vari-
ables, showing that the data were not normally distributed.
For this reason, all data were transformed, using the aligned
rank transformation [24]. All transformed data were further
analysed with repeated measures analysis of variance
(ANOVA). Two separate ANOVAs were performed: a two-
way ANOVA to study the influence of temperature and
different solutions on coagulation and a three-way ANOVA
to study the influence of added coagulation factors inhypothermia and haemodilution. Effects were presented as
estimated marginal means, i.e., the mean of a factor aver-
aged across all levels of the other factors. Where statistically
significant differences were detected, further investigations
of differences were made with contrast analysis. The
Bonferroni correction was used to adjust for multiple com-
parisons. The aligned rank transformation was calculated
with the free software ARTool. ANOVA statistical analysis
was performed using PASW 18 (SPSS). Data were consid-
ered significant when the P-value was <0.05.Results
FOR in hypothermia and haemodilution
In the first part of this study, the effects of mild
hypothermia and haemodilution, alone or in combin-
ation, were investigated.
Hypothermia
Mild hypothermia impaired all the measured aspects of
coagulation (Table 1 and Figure 2). Both the time to the
initiation phase (COT1) of coagulation and the time
to complete clot formation (COT2) were significantly
Table 1 Effects of hypothermia and haemodilution on coagulation measured with free oscillation rheometry (FOR)
Temperature Solution
Variable 37°C 33°C Undiluted RA HES
COT1 (s) 18.1 21.2 ** 17.6 20.1 ** 21.3 ***
COT2 (s) 58.3 68.8 *** 48.5 55.5 ** 86.7 ** †
G'max Fib1 (Pa) 716 613 *** 983 617 *** 395 *** †††
G'max Fib2 (Pa) 31.7 24.5 *** 43.3 29.5 *** 11.5 *** †††
G'max Fib1-2 (Pa) 685 589 ** 940 587 *** 383 *** †††
Effects on coagulation of hypothermia (33°C versus 37°C) and 33% haemodilution with RA or HES compared to undiluted blood, presented as estimated marginal
means. COT1 and COT2 are coagulation time 1 and 2, respectively. The maximal clot strength is presented as G'max for Fib1 (without platelet inhibition) and
G'max for Fib2 (with platelet inhibition). Platelet-dependent clot strength is presented by the difference between G'max for Fib1 and that for Fib2, denoted as
G'max Fib1-2.
** and *** stands for p < 0.01 and p < 0.001, respectively, when the two temperatures were compared or when diluted blood (RA or HES) was compared to
undiluted blood. †† and ††† stands for p < 0.01 and p < 0.001, respectively, when haemodilution with RA was compared to HES. See text for details on
interactions. N = 10.
A B
C
E
D
Figure 2 Effects of haemodilution and hypothermia on coagulation. Coagulation of undiluted, RA-diluted and HES-diluted blood at 33 and
37°C as assessed by FOR. The parameters COT1 (A), COT2 (B), maximum elasticity for FibScreen1 (C), maximum elasticity for FibScreen2 (D) and
the difference in maximum elasticity for FibScreen1 and 2 (E) are shown. Coagulation time 1 (COT1) represents the beginning of clot formation
and coagulation time 2 (COT2) a fully formed clot. G'max is the maximum elasticity of the fully formed clot. FibScreen1 (Fib1) denotes that
thromboplastin was added to the sample and FibScreen2 (Fib2) indicates that thromboplastin and abciximab were added, the latter a potent
platelet inhibitor. Thus, Fib1 G'max represents whole blood clot strength and Fib2 G'max fibrinogen-dependent clot strength. FS1 – FS2 G'max
was calculated to represent platelet-dependent clot strength. N = 10. Bars are 95% CI.
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weakened with hypothermia, measured as a decrease in
G'max. G'max decreased in whole blood (Fib1), in whole
blood with inhibited platelets (Fib2), as well as the calcu-
lated platelet-dependent (the difference between Fib1 and
Fib2) G'max.
Haemodilution
Haemodilution with RA or HES impaired all the measured
aspects of coagulation (Table 1 and Figure 2). Coagulation
times (COT1 and COT2) were prolonged and G'max
decreased in whole blood (Fib1), in whole blood with
inhibited platelets (Fib2), as well as the calculated platelet-
dependent clot strength. Haemodilution with HES consist-
ently impaired coagulation more than haemodilution with
RA. However, this difference was not statistically signifi-
cant for COT1 (Table 1).
Interaction of hypothermia and haemodilution
A significant interaction effect (synergy) was shown for
COT2 between hypothermia and haemodilution with HES
compared to undiluted blood (p = 0.035; hypothermia X
haemodilution (undiluted vs. HES)). COT2 was prolonged
after haemodilution with HES and even more when HES
haemodilution was combined with hypothermia (Figure 2).
Thus, hypothermia and haemodilution with HES prolonged
COT2 more than explained by their respective additive ef-
fects. Interestingly, this synergy could not be found between
hypothermia and haemodilution with RA.
Significant interaction effects were also shown for Fib2
G'max between hypothermia and haemodilution with HES
compared to either undiluted blood (p < 0.001) or blood di-
luted with RA (p = 0.003; Table 2). However, these statisti-
cally significant interactions were not proofs of synergy.
Instead they showed, as seen in Figure 2, that hypothermia
had less additional effect on Fib2 G'max in blood diluted
with HES, as compared to undiluted blood or blood dilutedTable 2 Interaction effects of (a) temperature and the type of
haemodilution and added coagulation factor
(a) Temperature X solution
Und Und. RA
Variable vs. RA vs. HES vs. HES
COT1 (s) - - -
COT2 (s) - 0.035 -
G'max Fib1 (Pa) - - -
G'max Fib2 (Pa) - <0.001 0.003
G'max Fib1-2 (Pa) - - -
Significances (p-values) of the interaction effects. The left half of the table (a) show
(Und. = undiluted, RA, or HES), according to a two-way ANOVA (Temperature X Solu
The right half of the table (b) shows the interaction between solution (RA or HES) a
fibrinogen or fibrinogen with FXIII), according to a three-way ANOVA (Temperature
interactions of Temperature X Coagulation Factor. None of these interactions were
platelet inhibition) and G'max for Fib2 (with platelet inhibition). Platelet-dependent
for Fib2, denoted as G'max Fib1-2. RA is Ringer’s acetate solution. HES is hydroxyethwith RA. The reason for this is probably technical, since
the FOR instrument never yields G'max values of <10 Pa.
After haemodilution with HES, FOR is simply unable to
detect any additional decreases in Fib2 G'max.
FOR in hypothermia and haemodilution with coagulation
factor substitution
In the second part of this study, the effects on coagula-
tion of adding factor concentrate (fibrinogen with or
without FXIII) in hypothermia and haemodilution were
studied.
Coagulation factor substitution
The overall effect of substitution with coagulation fac-
tors is presented in Table 3 and Figure 3. The addition
of fibrinogen significantly improved all FOR parameters,
except the initiation of coagulation (COT1). However, a
small additional effect when combining fibrinogen with
FXIII shortened COT1 significantly compared to the
control group without coagulation factors added. Apart
from this effect of FXIII on COT1, fibrinogen-dependent
clot strength, i.e., Fib2 G'max was the only parameter to
benefit further by combining fibrinogen with FXIII.
Thus, Fib2 G'max increased significantly after adding fi-
brinogen and rose significantly more when fibrinogen
was combined with FXIII. However, as seen in Figure 3,
Fib2 G'max increased with the addition of fibrinogen
(with or without FXIII) only in RA-diluted blood (see
below).
Interaction of type of solution in haemodilution and
addition of coagulation factor
There were significant interactions between the type of
solution in haemodilution and added coagulation factor
for COT2 and Fib2 G'max.
Adding fibrinogen (p = 0.001) or fibrinogen with FXIII
(p = 0.002) decreased COT2 more in blood diluted withsolution in haemodilution and (b) the type of solution in
(b) Solution X coagulation factor
Control vs. Control vs. Fibrinogen vs.
Fibr. Fibr. + FXIII Fibr. + FXIII
- - -
0.001 0.002 -
- - -
<0.001 <0.001 <0.001
- - -
s the interaction between temperature (33°C versus 37°C) and solution
tion).
nd added coagulation factor (Control, i.e., no addition of coagulation factor,
X Solution X Coagulation Factor). Not shown from the latter ANOVA are the
significant. The maximal clot strength is presented as G'max for Fib1 (without
clot strength is presented by the difference between G'max for Fib1 and that
yl starch in saline. Interactions marked with - were not significant. N = 10.
Table 3 Effects of added coagulation factors on
coagulation measured with free oscillation rheometry
(FOR)
Coagulation Factor
Variable Control Fibrinogen Fibrinogen + FXIII
COT1 (s) 20.7 19.4 19.0 **
COT2 (s) 71.1 55.2 *** 53.1 ***
G'max Fib1 (Pa) 506 585 ** 606 **
G'max Fib2 (Pa) 20.5 31.0 *** 36.3 *** ††
G'max Fib1-2 (Pa) 485 554 ** 570 **
Effects on coagulation of the coagulation factors fibrinogen, fibrinogen with
factor XIII (Fibrinogen + FXIII) or no addition of coagulation factor (Control).
Data are estimated marginal means. COT1 and COT2 are coagulation time 1
and 2, respectively. The maximal clot strength is presented as G'max for Fib1
(without platelet inhibition) and G'max for Fib2 (with platelet inhibition).
Platelet-dependent clot strength is presented by the difference between
G'max for Fib1 and that of Fib2, denoted as G'max Fib1-2. ** and *** stands
for p < 0.01 and p < 0.001, respectively, when the addition of coagulation
factor was compared to the control group. †† and ††† stands for p < 0.01 and
p < 0.001, respectively, when the addition of fibrinogen alone was compared
to the addition of fibrinogen with FXIII. See text for details on
interactions. N = 10.
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between fibrinogen and fibrinogen with FXIII.
On the contrary, Fib2 G'max increased more
after adding fibrinogen (p < 0.001) or fibrinogen with
FXIII (p < 0.001) in blood diluted with RA than in that
with HES. In fact, Fib2 G'max did not improve at all in
blood diluted with HES (Figure 3). In RA diluted blood,
Fib2 G'max increased most when fibrinogen was com-
bined with FXIII (p < 0.001).
Interaction of hypothermia and addition of coagulation
factor
There were no significant interactions between hypo-
thermia and the addition of any combination of coagula-
tion factors.Discussion
This study shows that cooling blood to 33°C and
haemodilution with HES interacts to impair clot formation.
We also found that fibrinogen substitution was effective
also at 33°C, alone or in combination with haemodilution.
The type of solution in haemodilution, however, did affect
the reversal effect of fibrinogen in dilutional coagulopathy.
After adding fibrinogen, clot propagation (COT2) im-
proved more in HES haemodilution, while fibrinogen-
dependent clot strength (Fib2 G'max) increased in RA
haemodilution only, and not at all in HES haemodilution.
Furthermore, combining fibrinogen with FXIII had an add-
itional effect on fibrinogen-dependent clot strength (Fib2
G'max) with RA haemodilution only. Apart from these
principle findings, we also confirmed the results of previ-
ous studies with other viscoelastic haemostatic assaysthat showed that both hypothermia and haemodilution in-
dependently impaired coagulation, and that HES impaired
coagulation more than RA.
VHAs such as thrombelastography, measure coagula-
tion in whole blood rather than in plasmaand they are
therefore able to detect interactions between platelets, red
blood cells and coagulation factors. Thus, VHAs more ac-
curately describe coagulation in vivo and they are better
predictors of bleeding than traditional measures of coagu-
lation [25]. FOR’s ability to measure viscosity changes en-
ables detection of the start of clot formation (COT1),
which is in contrast to with thrombelastography. FOR uses
free oscillation, which results in less strain on the clot as
compared with thrombelastography. Compared to max-
imal clot strength measured with thrombelastography, the
corresponding measure with FOR (Fib1 G'max) is more
dependent on platelets than on factors affecting the
fibrinogen polymerization, i.e. fibrinogen concentration
and FXIII [21]. Thus, FOR may provide new information
on the effect of hemodilution and hypothermia on
coagulation.
In concordance with earlier studies with VHAs, we
found that hypothermia impaired clot formation variables
[18,26]. In addition, we observed that clot strength was de-
creased even by mild hypothermia, which other studies
failed to detect [19,27]. Previous studies only noted this
decrease in clot strength during moderate to severe
hypothermia [18,26]. The different measuring principles of
ROTEM and FOR might be the cause of the different ef-
fects observed on clot strength by hypothermia. The pos-
sible higher sensitivity of clot strength variables measured
with the FOR than with other methods is interesting.
However, the decrease in clot strength observed from 37°
to 33°C is moderate and unlikely to have any clinical
implications.
Our results demonstrated that haemodilution with ei-
ther HES or RA compromised coagulation, and that the
effect of HES was more pronounced. This is in accordance
with previous studies where HES was shown to affect co-
agulation more than RA both in vitro [28,29] and in vivo
[30,31]. It is believed that HES, in contrast to crystalloids,
also impair fibrinogen/fibrin polymerization [29].
Not only platelets are important cellular components of
global haemostasis, but also erythrocytes play an import-
ant role [32]. The role of the haematocrit level has been
previously studied. In vitro studies with FOR and TEG,
where the platelet counts were held constant, showed in-
creased clot strengths with decreasing haematocrit levels
[21,33]. This increase in clot strength may be due to in-
creasing fibrinogen levels after haemodilution with
plasma. Ogawa recently also showed an increase in clot
strength after haemodilution with plasma [34]. However,
at a given fibrinogen concentration, clot strength instead
improved with falling haematocrit levels. Thus, fibrinogen
A B
C
E
D
Figure 3 Effects of factor concentrate addition on coagulation. Coagulation of RA-diluted and HES-diluted blood at 33 and 37°C upon
addition of factor concentrates (fibrinogen or fibrinogen + FXIII) as assessed by FOR. The parameters COT1 (A), COT2 (B), maximum elasticity for
FibScreen1 (C), maximum elasticity for FibScreen2 (D) and the difference in maximum elasticity for FibScreen1 and 2 (E) are shown. Coagulation
time 1 (COT1) represents the beginning of clot formation and coagulation time 2 (COT2) a fully formed clot. G'max is the maximum elasticity of
the fully formed clot. FibScreen1 (Fib1) denotes that thromboplastin was added to the sample and FibScreen2 (Fib2) indicates that
thromboplastin and abciximab were added, the latter a potent platelet inhibitor. Thus, Fib1 G'max represents whole blood clot strength and Fib2
G'max fibrinogen-dependent clot strength. FS1 – FS2 G'max was calculated to represent platelet-dependent clot strength. N = 10. Bars are 95% CI.
Winstedt et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2013, 21:20 Page 7 of 9
http://www.sjtrem.com/content/21/1/20levels seem to be far more important than haematocrit
level for the final clot strength.
Other studies have not found any interaction effects be-
tween hypothermia and haemodilution, as assessed by co-
agulation time and clot strength [35,36]. We discerned no
interactions for the clot strength variables, but we did find
significant interaction effects between hypothermia and
haemodilution with HES in the time to complete clot for-
mation (COT2). There was also a tendency towards inter-
action between hypothermia and haemodilution with RA
for the time to complete clot formation (COT2), as well as
between hypothermia and haemodilution with both solu-
tions for the initiation of clot formation (COT1). FOR
and thrombelastography are not completely comparable
methods. For example, in contrast to thrombelastography,
FOR can measure viscosity changes and discerns the co-
agulation time from the changes in viscosity. This mayexplain the inability of thrombelastography to detect any
interaction effects on variables describing the early phases
of coagulation.
Substitution with fibrinogen concentrate in dilutional
coagulopathy has been demonstrated to effectively in-
crease clot strength [9,10,13] and to reduce bleeding
[11,37]. A high ratio of fibrinogen to red blood cell trans-
fusion is associated with improved survival rates [38]. In
this study, we found that fibrinogen increased clot
strength and shortened the coagulation time (COT1 and
COT2). The reduction in COT1, though, was very small
and significant only when fibrinogen was combined with
FXIII. These results are in agreement with the aforemen-
tioned studies with ROTEM, where addition of fibrinogen
increased clot strength, while the coagulation time (CT)
failed to improve after addition of fibrinogen [9,13]. Inter-
estingly, fibrinogen supplementation decreased COT2
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that with RA, while fibrinogen-dependent clot strength in-
creased more in haemodilution with RA. In fact, Fib2
G'max did not increase at all after adding fibrinogen or fi-
brinogen combined with FXIII in haemodilution with
HES. In other words, fibrinogen substitution reversed the
early phases of the coagulation regardless of the presence
of starch, while haemodilution with HES made fibrinogen
unable to improve clot strength. One may speculate that
higher doses of fibrinogen may be required to improve
also clot strength after HES haemodilution.
FXIII’s activity is diminished by haemodilution [39].
FXIII is ineffective at correcting dilutional coagulopathy
in vitro [10], but has been shown to decrease post-
operative chest-drain bleeding after cardiac surgery [40].
Combining fibrinogen with FXIII in RA haemodilution
had an additional on Fib2 G'max but no effect on Fib1
G'max, as discussed above. The additional increase of Fib1
G'max after adding FXIII together with fibrinogen is small
(not significant) and will be masked by the platelets when
assessing Fib1 G'max. Therefore, analysis of Fib2 G'max
will add important information on factors affecting the fi-
brinogen polymerization.
The findings of this study emphasise the importance of
reversing hypothermia and avoiding haemodilution. As
previously concluded, it is reasonable to avoid HES in cases
of major haemorrhages. Our study showed that the
addition of fibrinogen was also beneficial in mild
hypothermia and thus, patients are not required to be
warmed before infusing fibrinogen. Moreover, if HES has
been used in seriously bleeding patients, higher doses than
those given in this study are probably needed to re-
establish adequate clot strength. Finally, combining fibrino-
gen with FXIII may be worthwhile in RA induced coagu
lopathy, since this combination improved fibrinogen-
dependent clot strength (Fib2 G'max) more than fibrino-
gen alone in this in vitro study. However, controlled clinical
studies need to be undertaken with FOR, to establish cor-
rect doses of fibrinogen and factor XIII in dilutional
coagulopathy.
In contrast to other studies, we studied the combination
of concurrent hypothermia, haemodilution and coagula-
tion factors. We chose to study mild hypothermia and
moderate haemodilution, since we wished to study a com-
mon and clinically relevant situation. Unfortunately, this
decreased the power to detect any statistical differences.
Furthermore, FOR is not a widely used method in investi-
gations of coagulopathy in bleeding patients. However,
comparison with studies using thrombelastography
(ROTEM and TEG) is logical, since FOR is very similar to
thrombelastography and these methods are good predic-
tors of perioperative bleeding. There are several other
limitations to performing in vitro haemodilution studies
using citrated blood, as is the case in this study. Thesituation in vitro may not accurately represent the situation
in vivo. For example, in vitro models do not account for
shear stress, release of tissue factor by the endothelium,
and activation of procoagulation or fibrinolytic pathways in
response to tissue trauma. Our study was performed in
blood from healthy volunteers, whereas trauma patients
may exhibit a wide range of coagulopathies.
Conclusions
In conclusion, this in vitro study shows that hypothermia
at 33°C combined with 33% haemodilution, especially with
HES, interact to impair coagulation variables measured
with free oscillation rheometry (FOR). These effects were
reduced by adding fibrinogen regardless of hypothermia at
33°C. After haemodilution with RA, coagulation variables
were improved by fibrinogen, but clot strength was not
improved with fibrinogen after haemodilution with HES.
Further, FXIII had an additional effect on the effects
of fibrinogen substitution, at least on the fibrinogen-
dependant clot strength. In summary, higher fibrinogen
doses than previously recommended may be required to
reverse HES-induced coagulopathy and the combination
of fibrinogen with factor XIII may be beneficial. Further
clinical investigations are needed to establish the optimal
dose of fibrinogen and to elucidate the role of FXIII in
dilutional coagulopathy.
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